
Researchers develop more reliable platform to test antibody medicines
Ghent, 30 January 2026 – An international research consortium has validated a new platform that could change how antibody medicines are tested and brought to patients. The work, published in Science Immunology, highlights problems during conventional antibody drug testing and introduces a next-generation mouse model that makes it possible to predict the effects of antibody drugs in humans more accurately.
Latest stories

Researchers uncover axonal protein synthesis defect in ALS
Leuven, January 12, 2026 – Researchers at VIB and KU Leuven have identified a molecular process that allows motor neurons to maintain protein production, a process that fails in amyotrophic lateral sclerosis (ALS). The study, published in Nature Neuroscience, reveals an early weakness in neurodegeneration and highlights a potential target for future therapies.
Key lung immune cells can intensify allergic reactions
New research by scientists at VIB and UGent reveals that immune cells in the lung, long thought to protect against inflammation, can, under certain conditions, make allergic reactions such as asthma worse. Their work appears in the journal Immunity.

RSV vaccines could offer protection against asthma
Ghent, November 28, 2025 – Belgian scientists from VIB and Ghent University (UGent), together with Danish collaborators, have uncovered compelling evidence that early-infancy infection with respiratory syncytial virus (RSV) significantly increases the risk of developing childhood asthma—especially in children with a family history of allergy or asthma. Their study, published today in Science Immunology, suggests that protecting newborns against RSV could substantially reduce asthma cases later in life.
Contact us



.jpg)


